State Drug Firms Seek Diversification In India
This article was originally published in PharmAsia News
Executive Summary
State-run pharmaceutical companies in India seek to take advantage of their large land holdings to diversify into developing commercial complexes in information-technology parks they also run. Bengal Chemicals and Pharmaceuticals is building a large office complex on two acres it owns in Mumbai and plans to lease space while it pursues its drug-development business. Indian Drugs and Pharmaceuticals plans a similar arrangement at the four locations where it will include biotech parks. The state entities still need clearance from a group of government ministers before they can follow through with their diversification plans. (Click here for more
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.